The significance of metaiodobenzylguanidine scintigraphy in the treatment of high risk neuroblastomas
Open Access
- 1 January 2020
- journal article
- research article
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinski podmladak
- Vol. 71 (1) , 26-32
Abstract
Introduction: Neuroblastoma cells show the expression of norepinephrine transporters enabling the intercellular location of mIBG, which turned out to be ideal for the visualization of neuroblastoma, as well as for the treatment of these tumors in certain cases. Aim: The aim of this retrospective analysis is to show the possibilities of the 131/123J-mIBG scintigraphy in detecting primary tumor as well as in determining the presence and localization of metastatic lesions in children with neuroblastoma. Material and methods: The investigation was carried out in 17 subjects, 7 boys and 10 girls, aged 8.2 ± 7.8 (4 months to 16 years). In 10 of them the IV neuroblastoma was confirmed. A number of 7 children underwent only the diagnostic scintigraphy while in 10 of them 2-5 scans with 123/131J-mIBG were performed during follow-up. In total, there were 35 scintigraphy for the analysis. Results: A negative finding of 123/131J-mIBG scan was observed in 8 subjects. In one of them, neuroblastoma was histopathologically proven, but the scintigraphy was performed after the surgical removal of the tumor and after chemotherapy. In 9 children with scintigraphically confirmed neuroblastoma, apart from having the primary tumor, the metastatic spread of the disease was detected in the bone marrow during the initial staging. After the treatment, 4 children had a negative finding on mIBG scintigraphy, which indicated the remission, while in 2 children, the tumor relapsed; and in 4 of them, the regression of the tumor occurred after the treatment. Conclusion: The results showed high sensitivity of 123/131J-mIBG scintigraphy in detecting neuroblastoma, both the primary tumor and metastases in the bone marrow. This radiopharmaceutical turned out to be reliable for the treatment monitoring of children with neuroblastoma. Likewise, a high incidence of bone metastases was detected on the mIBG scintigraphy, as well as a the high rate of disease recurrence after therapy.Keywords
This publication has 9 references indexed in Scilit:
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task ForceBritish Journal of Cancer, 2010
- 123I‐mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trialPediatric Blood & Cancer, 2009
- The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97European Journal of Cancer, 2008
- Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology GroupJournal of Clinical Oncology, 2005
- Staging of Neuroblastoma at Imaging: Report of the Radiology Diagnostic Oncology GroupRadiology, 2002
- The Neural Crest1999
- Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring systemCancer, 1996
- Neuroblastoma, Its Natural History and Prognosis: A Study of 487 CasesBMJ, 1974